According to our new research study on “Australia Lung Cancer Screening Market Size and Forecast to 2030 – COVID-19 Impact and Country Analysis – by Cancer Type, Technology, Age Group, and End User,” the market is expected to grow from US$ 2.74 million in 2022 to US$ 6.12 million by 2030; it is estimated to record a CAGR 10.6% during 2022–2030. Factors like the Increasing incidence of lung cancer and rising government support are driving the Australia lung cancer screening market size and growth.

Market Trends

Mobile Lung Cancer Screening Truck

After the National Health Services (NHS) started on-the-spot chest screening, early diagnosis of lung cancer was initiated globally. However, people in remote areas/communities have less access to early-stage lung cancer diagnostic tools and are more likely to register higher mortality rates as compared to urban areas. Therefore, mobile trucks that provide detect lung cancer screening in remote areas are expected to assist in diagnosing early-stage lung cancer by approaching communities.

Further, per a published report by the University of Queensland Australia 2023, as a part of Australia$ 2 million Australian Cancer Research Foundation (ACRF) grant, a semi-trailer truck is expected to be converted into the world's first mobile lung cancer screening facility to help boost early detection and increase survival rates in rural and remote Queensland, where access to specialists is limited. The truck will be equipped with the latest technologies that integrate imaging, breath, and blood biomarker screening. The ACRF Lung Cancer Screening Center of Excellence (LUSCE) mobile facility will target Australians living in rural and remote areas, as well as indigenous communities with limited access to lung cancer screening facilities. Thus, the increasing awareness of the mobile lung cancer screening truck facility is likely to catalyze the growth of the Australia lung cancer screening market during the forecast period.

Based on age group, the Australia lung cancer screening market is bifurcated into 50 & older and below 50. In 2022, the 50 & older segment held the largest share of the market. However, the below 50 segment is expected to grow at the fastest rate during the coming years. Lung cancer is commonly found in the aged population and often does not cause symptoms until it is more advanced. Nevertheless, screening for lung cancer for high-risk individuals can help find and treat it promptly.

According to Cancer Council Australia, more than 14,500 individuals were diagnosed with lung cancer in 2022. The average age at diagnosis is 71 years. Furthermore, lung cancer is the fifth most commonly diagnosed cancer in Australia, and it is projected that one in 20 people will be diagnosed by age 85. The aforementioned factors are responsible for influential segmental growth ultimately accounting maximum market size and growth of Australia lung cancer screening market growth till 2030.

Likewise, According to the American Cancer Society Trusted Source, most individuals diagnosed with lung cancer are 65 years and older, with an average age at diagnosis being 70 years. Only a small number of individuals are diagnosed at 45 or younger.

The Centers for Disease Control and Prevention (CDC) put together rates of diagnosis of new lung cancers by age group.

The case counts per 100,000 people are as follows:

The aforementioned factors are responsible for influential segmental growth thereby recording maximum CAGR for the Australia lung cancer screening market size and growth for 2022-2030.

Intelerad Medical Systems Incorporated, Nuance Communications Inc, GE HealthCare Technologies Inc, Medtronic Plc, Canon Medical Systems Corp, Koninklijke Philips NV, Siemens AG, Aetna Inc, bioAffinity Technologies, Inc., LungLife AI, Inc., and Lung Screen Australia Pty Ltd among others in the Australia lung cancer screening market. Leading players adopt strategies such as the launch of new products, expansion and diversification of their market presence, and expansion of new customer base for tapping prevailing business opportunities.

The report segments Australia Lung Cancer Screening Market as follows:

The Australia lung cancer screening market is segmented on the basis of  cancer type, technology, age group, and end user. non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The non-small cell lung cancer (NSCLC) segment held the largest share of the market in 2022 and small cell lung cancer (SCLC) is anticipated to register the highest CAGR in the market during the forecast period. Based on technology, the Australia lung cancer screening market is segmented as chest X-ray, low-dose computed tomography (LDCT), liquid biopsy, and others. Chest X-ray segment will account maximum share and low-dose computed tomography (LDCT) segment will record highest CAGR for Australia lung cancer screening market for the forecast period 2022-2030. By age-group, the market is segmented as 50 & older and below 50. The 50 & older segment will account maximum share and below 50 segment will record highest CAGR for the Australia lung cancer screening market for the forecast period of 2022-2030. By end user, the Australia lung cancer screening market is segmented into hospitals, diagnostic centers, and others. The hospitals segment will account highest market share and others segment will record highest CAGR for Australia lung cancer screening market for the forecast period of 2022-2030.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com